With the burgeoning interest in novel treatments for metabolic syndrome and weight management, a head-to-head assessment of Tirzepatide and the dual GIP and GLP-1 receptor agonist has become essential. While both therapies function through akin mechanisms – targeting glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide bindin… Read More